上海医药(02607.HK)：普瑞巴林胶囊获得新加坡药品注册证书

Core Viewpoint - Shanghai Pharmaceuticals (02607.HK) announced that its subsidiary, Changzhou Pharmaceutical Factory, has received a drug registration certificate from the Health Sciences Authority (HSA) of Singapore for Pregabalin capsules, which have been approved for market launch [1] Group 1 - The approved drug, Pregabalin capsules, is primarily used for the treatment of postherpetic neuralgia, diabetic peripheral neuropathy, fibromyalgia, and neuropathic pain due to spinal cord injury, as well as for adjunctive treatment of epilepsy [1]